The consensus among analysts is that Miragen Therapeutics (MGEN) is an Overweight stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 5 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.16.

Miragen Therapeutics (NASDAQ:MGEN) trade information

Sporting 2.91% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the MGEN stock price touched $1.59 or saw a rise of 33.33%. Year-to-date, Miragen Therapeutics shares have moved 120.88%, while the 5-day performance has seen it change -25.35%. Over the past 30 days, the shares of Miragen Therapeutics (NASDAQ:MGEN) have changed 7.4%. Short interest in the company has seen 490.8 Million shares shorted with days to cover at 293.89.

Miragen Therapeutics (MGEN) estimates and forecasts

Figures show that Miragen Therapeutics shares have underperformed across the wider relevant industry. The company’s shares have gained +108.62% over the past 6 months, with this year growth rate of -58.21%, compared to 9.2% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 44.8% and 58.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be -67.9%.

4 analysts offering their estimates for the company have set an average revenue estimate of $290Million for the current quarter. 4 have an estimated revenue figure of $270Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $260Million and $695Million respectively for this quarter and the next, and analysts expect sales will grow by 11.5% for the current quarter and -61.2% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +52% over the past 5 years. Earnings growth for 2020 is a modest -20.9% while over the next 5 years, the company’s earnings are expected to increase by 0%.

Miragen Therapeutics (NASDAQ:MGEN)’s Major holders

Insiders own 5.66% of the company shares, while shares held by institutions stand at 16.94% with a share float percentage of 17.96%. Investors are also buoyed by the number of investors in a company, with Miragen Therapeutics having a total of 32 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 3.89 Million shares worth more than $1.73 Million. As of March 30, 2020, FMR, LLC held 7.33% of shares outstanding.

The other major institutional holder is Atlas Venture Advisors, Inc., with the holding of over 3.14 Million shares as of March 30, 2020. The firm’s total holdings are worth over $1.4 Million and represent 5.92% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. As of March 30, 2020, the former fund manager holds about 7.33% shares in the company for having 3888656 shares of worth $1.73 Million while later fund manager owns 1.21 Million shares of worth $537.84 Thousand as of March 30, 2020, which makes it owner of about 2.27% of company’s outstanding stock.